Informed Burn-In Decisions in RAR: Harmonizing Adaptivity and Inferential Precision Based on Study Setting
By: Lukas Pin , Stef Baas , Gianmarco Caruso and more
Potential Business Impact:
Finds best time to change treatment plans.
Response-Adaptive Randomization (RAR) is recognized for its potential to deliver improvements in patient benefit. However, the utility of RAR is contingent on regularization methods to mitigate early instability and preserve statistical integrity. A standard regularization approach is the ''burn-in'' period, an initial phase of equal randomization before treatment allocation adapts based on accrued data. The length of this burn-in is a critical design parameter, yet its selection remains unsystematic and improvised, as no established guideline exists. A poorly chosen length poses significant risks: one that is too short leads to high estimation bias and type-I error rate inflation, while one that is too long impedes the intended patient and power benefits of using adaptation. The challenge of selecting the burn-in generalizes to a fundamental question: what is the statistically appropriate timing for the first adaptation? We introduce the first systematic framework for determining burn-in length. This framework synthesizes core factors - total sample size, problem difficulty, and two novel metrics (reactivity and expected final allocation error) - into a single, principled formula. Simulation studies, grounded in real-world designs, demonstrate that lengths derived from our formula successfully stabilize the trial. The formula identifies a ''sweet spot'' that mitigates type-I error rate inflation and mean-squared error, preserving the advantages of higher power and patient benefit. This framework moves researchers from conjecture toward a systematic, reliable approach.
Similar Papers
A burn-in(g) question: How long should an initial equal randomization stage be before Bayesian response-adaptive randomization?
Methodology
Helps doctors test new medicines fairly and safely.
Stabilizing Thompson Sampling with Point Null Bayesian Response-Adaptive Randomization
Methodology
Helps doctors give patients the best medicine faster.
Safety-Driven Response Adaptive Randomisation: An Application in Non-inferiority Oncology Trials
Methodology
Helps cancer drugs get to patients faster.